<DOC>
	<DOCNO>NCT02643693</DOCNO>
	<brief_summary>This study provide initial assessment acceptability Nicotine Lactate Delivery System ( P3L ) ad libitum use ability combustible cigarette ( CC ) smoker use P3L maintain customary nicotine intake . The pharmacokinetics ( PK ) pharmacodynamics ( PD , i.e. , subjective effect ) profile , evaluate well safety tolerability P3L .</brief_summary>
	<brief_title>User Acceptability P3L</brief_title>
	<detailed_description>The total duration study individual subject 3 8 week , include 1 day screen visit , 3 day ad libitum use session ( P3L , VUSE e-cigarette system subject ' commercially available non-menthol CC ) , 1 day preference evaluation session ( subject give choice use ad libitum P3L VUSE ) , 2 10 day interval visit , 7 day passive safety follow-up period .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Smoking , healthy subject judge Investigator Subject smoke least 10 commercially available nonmenthol CCs per day last 12 month Subject plan quit smoke next 60 day As per Investigator judgment , subject participate study reason ( e.g. , medical , psychiatric , and/or social reason ) Subject donate receipt whole blood blood product within 3 month prior screen visit Subject use tobacco product nicotine contain product CCs within 30 day prior screen visit Female subject pregnant breast feed Female subject agree use acceptable method effective contraception Female subject us estrogencontaining hormonal contraception hormone replacement therapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Conventional cigarette</keyword>
	<keyword>Nicotine lactate delivery system</keyword>
	<keyword>e-cigarette</keyword>
	<keyword>VUSE</keyword>
	<keyword>Combustible cigarette</keyword>
</DOC>